drug
icotrokinra hydrochloride
Marketedupdated 6mo agoby $JNJ JOHNSON & JOHNSON
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
IBD (Crohn's + UC)
all catalysts(1)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 12, 2039
~12.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Nov 19, 2041formulationUS 11939361
- Jan 14, 2041compositionUS 11845808
- Jul 12, 2039compositionUS 12552836
News(10)
- J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reignA Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…biospace · 10d ago
- Argenx inks $1.15B Unnatural Products buyout to expand in oral peptidesArgenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.fiercebiotech · 10d ago
- China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis winA phase 3 trial of InventisBio’s nomelcitinib has hit its primary endpoint, delivering evidence that the TYK2 inhibitor can hold its own against rival psoriasis drugs.fiercebiotech · 17d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 22d ago
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsA patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.biopharma_dive · 24d ago
- Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s IcotydeGilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across…fiercebiotech · 27d ago
- Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits againBausch + Lomb CEO Brent Saunders is making a second exit from the eye health company, as the president of parent Bausch Health steps in temporarily. Plus, Paragon Labs is buying out Apogee talent a…fiercebiotech · 1mo ago
- J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentWhile innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.biospace · 1mo ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 2mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that